These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38316017)

  • 1. Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma.
    Chang Q; Li J; Deng Y; Zhou R; Wang B; Wang Y; Zhang M; Huang X; Li Y
    J Med Chem; 2024 Feb; 67(4):2466-2486. PubMed ID: 38316017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong
    Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y
    J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins.
    Thomas JE; Wang M; Jiang W; Wang M; Wang L; Wen B; Sun D; Wang S
    J Med Chem; 2023 Jun; 66(12):8178-8199. PubMed ID: 37276143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.
    Wu T; Hu J; Zhao X; Zhang C; Dong R; Hu Q; Xu H; Shen H; Zhang X; Zhang Y; Lin B; Wu X; Xiang Q; Xu Y
    J Med Chem; 2024 Jun; 67(11):9194-9213. PubMed ID: 38829718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting p300/CBP Attenuates Hepatocellular Carcinoma Progression through Epigenetic Regulation of Metabolism.
    Cai LY; Chen SJ; Xiao SH; Sun QJ; Ding CH; Zheng BN; Zhu XY; Liu SQ; Yang F; Yang YX; Zhou B; Luo C; Zhang X; Xie WF
    Cancer Res; 2021 Feb; 81(4):860-872. PubMed ID: 33361394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
    Chen Z; Wang M; Wu D; Zhao L; Metwally H; Jiang W; Wang Y; Bai L; McEachern D; Luo J; Wang M; Li Q; Matvekas A; Wen B; Sun D; Chinnaiyan AM; Wang S
    J Med Chem; 2024 Apr; 67(7):5351-5372. PubMed ID: 38530938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic regulation of proliferation and invasion in hepatocellular carcinoma cells by CBP/p300 histone acetyltransferase activity.
    Inagaki Y; Shiraki K; Sugimoto K; Yada T; Tameda M; Ogura S; Yamamoto N; Takei Y; Ito M
    Int J Oncol; 2016 Feb; 48(2):533-40. PubMed ID: 26676548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of new RNF126-based p300/CBP degraders.
    Lei YH; Tang Q; Ni Y; Li CH; Luo P; Huang K; Chen X; Zhu YX; Wang NY
    Bioorg Chem; 2024 Jul; 148():107427. PubMed ID: 38728911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
    Vannam R; Sayilgan J; Ojeda S; Karakyriakou B; Hu E; Kreuzer J; Morris R; Herrera Lopez XI; Rai S; Haas W; Lawrence M; Ott CJ
    Cell Chem Biol; 2021 Apr; 28(4):503-514.e12. PubMed ID: 33400925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of anticancer activity of CBP/p300 inhibitors - Features of their classes, intracellular targets and future perspectives of their application in cancer treatment.
    Strachowska M; Robaszkiewicz A
    Pharmacol Ther; 2024 May; 257():108636. PubMed ID: 38521246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current development of CBP/p300 inhibitors in the last decade.
    He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
    Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
    Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
    J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Novel PROTAC SIRT6 Degraders with Potent Efficacy against Hepatocellular Carcinoma.
    Huang J; Su J; Wang H; Chen J; Tian Y; Zhang J; Feng T; Di L; Lu X; Sheng H; Zhu Q; Chen X; Wang J; He X; Yerkinkazhina Y; Xie Z; Shu Y; Kang T; Tang H; Qian J; Zhu WG
    J Med Chem; 2024 Oct; 67(19):17319-17349. PubMed ID: 39323022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.
    Popp TA; Tallant C; Rogers C; Fedorov O; Brennan PE; Müller S; Knapp S; Bracher F
    J Med Chem; 2016 Oct; 59(19):8889-8912. PubMed ID: 27673482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer.
    Ma M; Li M; Zhang C; Yang Z; Chen X; Lu P; Nie S; Zhang S; Ma S; Qin C
    J Med Chem; 2024 Sep; ():. PubMed ID: 39344125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
    Luo J; Chen Z; Qiao Y; Tien JC; Young E; Mannan R; Mahapatra S; He T; Eyunni S; Zhang Y; Zheng Y; Su F; Cao X; Wang R; Cheng Y; Seri R; George J; Shahine M; Miner SJ; Vaishampayan U; Wang M; Wang S; Parolia A; Chinnaiyan AM
    bioRxiv; 2024 May; ():. PubMed ID: 38586029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors.
    Xiong Y; Zhang M; Li Y
    Curr Med Chem; 2020; 27(33):5583-5598. PubMed ID: 31364510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of bromodomain ligand-linker conjugation sites for efficient CBP/p300 heterobifunctional degrader activity.
    Kumar Tiwari P; Reddy Doda S; Vannam R; Hudlikar M; Harrison DA; Ojeda S; Rai S; Koglin AS; Nguyen Gilbert A; Ott CJ
    Bioorg Med Chem Lett; 2024 Apr; 102():129676. PubMed ID: 38408512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
    Chen Z; Wang M; Wu D; Bai L; Xu T; Metwally H; Wang Y; McEachern D; Zhao L; Li R; Takyi-Williams J; Wang M; Wang L; Li Q; Wen B; Sun D; Wang S
    J Med Chem; 2024 Apr; 67(7):5275-5304. PubMed ID: 38477974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CRISPR Interference of CBP and p300 Selectively Induced Synthetic Lethality in Bladder Cancer Cells
    Li J; Huang C; Xiong T; Zhuang C; Zhuang C; Li Y; Ye J; Gui Y
    Int J Biol Sci; 2019; 15(6):1276-1286. PubMed ID: 31223286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.